Fachinformation, Stand 09/2020, www.swissmedicinfo.ch
www.pptaglobal.org/safety-quality/standards/qseal
Lai et al. (2017) : Biological considerations of plasma-derived and recombinant factor VIII immunogenicity. Blood, 129(24): 3147-3154.
Delignat et al. (2012) : Immunoprotective effect of von Willebrand factor towards therapeutic factor VIII in experimental haemophilia A. Haemophilia , 18(2): 248-254.
Herceznik et al. (2012) : Uptake of blood coagulation factor VIII by dendritic cells is mediated via its C1 domain. J Allergy Clin Immunol, 129(2): 501-509.
Shi et al. (2012): Factor VIII inhibitors: von Willebrand factor makes a difference in vitro and in vivo. J Thromb Haemost. 10(11): 2328-2337.
Mannucci P.M. & Garagiola I. (2015): Factor VIII products in haemophilia A: one size fits all ?, Thromb Haemost. 113(5): 911-914.
Peyvandi et al. (2016) : A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A. N Engl J Med, 374(21): 2054-2064.
Mahlangu et al. (2018) : Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors. N Engl J Med, 379(9): 811-822.
Tiede A. (2015) : Half-life extended factor VIII for the treatment of hemophilia A. J Thromb Haemost, 13: 179-179.
Calvez et al. (2018) : Analyses of the FranceCoag cohort support differences in immunogenicity among one plasma-derived and two recombinant factor VIII brands in boys with severe hemophilia A. Haematologica, 103(1), p. 179- 189